About 6,000 attendees are expected for the meeting next week that will also have Adam Fein and Doug Long as featured speakers.
Former FDA Commissioner Scott Gottlieb, M.D., is the featured keynote speaker at Asembia’s 2022 Annual Specialty Pharmacy Summit in Las Vegas.
About 6,000 people are expected to attend the meeting, which starts Monday, May 2, and ends Wednesday, May 5.
In addition to Gottlieb, featured speakers at the meeting’s three general sessions on May 3 include Adam Fein, CEO of the Drug Channels Institute, one of the country’s foremost experts on drug pricing and the dynamics of the pharmaceutical market, and Doug Long, vice president of industry relations at IQVIA, whose rapid-fire overviews of U.S. healthcare and drug trends are featured at many medical meetings.
Fein and Gottlieb are scheduled to have a “fireside” discussion after Gottlieb speaks Wednesday morning.
A third general session on Wednesday will feature a panel of four industry leaders: Rina Shah, group vice president, pharmacy & services, at Walgreens; Natalie Bedford, senior vice president, specialty pharmacy, at Humana; Lucille Accetta, senior vice president of pharmacy benefit management and specialty product development at CVS Health; and Michael Einodshofer, chief pharmacy officer at OptumRx. The moderator of the panel is Bruce Japsen, a senior contributor at Forbes who covers the healthcare.
The meeting’s agenda includes 24 continuing education sessions on a variety of fairly specific clinical topics: PARP inhibitors for treatment of ovarian cancer, optimal use of anti-androgen therapies, newly approved and emerging IgA nephropathy treatments
There are also 42 business sessions about policy and business developments affecting the specialty pharmacy industry and healthcare overall. The topics being covered in those business sessions include biosimilar adoption, digital therapeutics, the 340B program, value-based contracting, patient-reported outcomes, and the Biden administration’s healthcare agenda.
As of April 4, 157 companies and organizers had signed up to be exhibitors at the meeting.
The meeting is being held Wynn & Encore hotel.
Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, shared results yesterday of a survey that look at biosimilars on the pharmacy benefit side of coverage versus medical benefit. The survey also shared how payers and those on the pharmaceutical side are anticipating the introduction of Adalimumab (Humira®), as well as what to look for in the future of the biosimilar pipeline.
Read More
The Healthcare World According to Fein | 2023 Asembia Specialty Pharmacy Summit
May 3rd 2023Adam Fein, Ph.D., talked about some surprising trends in specialty pharmacy and healthcare at the 2023 Asembia Specialty Pharmacy Summit. The number of specialty pharmacy locations may be peaking. And that "gross-to-net bubble" in drug prices that Fein has written about so much — well, it may be shrinking.
Read More